Nonsmall cell lung cancerImmune checkpoint inhibitorsImmunotherapyChemoimmunotherapyOver the last decade, the use of immune checkpoint inhibitors (ICI) has dramatically changed the treatment paradigm and outcome of patients with nonsmall cell lung cancer (NSCLC) across all stages of the disease. In ...
benefitontheoutcomeofneoadjuvantchemotherapyininEurope.Nonsmall-celllungcancer(NSCLC) patientswithearly-stagenonsmall-celllungcancerandrepresentsapproximay80%ofalllungcancers. comparethisevidencewiththetheoreticaladvantagesandSurgeryremainsthecornerstoneoftreatmentfor ...
Chemosensitization in non-small cell lung cancer cells by IKK inhibitor occurs via NF-kappaB and mitochondrial cytochrome c cascade. J. Cell Mol. Med.,... Zhang,Zhang,Wang,... 被引量: 0发表: 0年 Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck...
Expert opinion: First line chemo-immunotherapy combinations are starting to and will certainly revolutionize the current paradigm of metastatic non small cell lung cancer treatment due to their superior performances - both in terms of PFS and OS - when compared to the actual standard of care ...
l cell lung cancer) Survival not better with chemo for early NSCLC.(Pulmonary Medicine)(non-small cell lung cancer)Survival not better with chemo for early NSCLC.(Pulmonary Medicine)(non-small cell lung cancer)MacNeil, Jane Salodof
Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) as the most common subtype. In the past decades, immunotherapy deeply changed paradigms for care of newly diagnosed advanced NSCLC patients without oncogenic driver mutations. An immunotherapy...
For advanced non- small cell lung cancer (NSCLC), targeting immune checkpoint pathways has proven to be less toxic with more durable treatment response than conventional chemotherapy. In inoperable Stage III NSCLC, consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab after ...
The goal of this work was to develop a mathematical model to predict Kaplan–Meier survival curves for chemotherapy combined with radiation in Non-Small Cell Lung Cancer patients for use in clinical trial design. The Gompertz model was used to describe t
neoadjuvant chemo-/radiotherapy in locally advanced non-small cell lung cancer: m. von eiff, w. wagner, a. geiger, v. klinke, j. van de loo; department of internal medicine, münster, germany-在局部晚期非小细胞肺癌的新辅助chemo-/radiotherapy:A. W.瓦格纳,M.冯Eiff,盖格,J. VAN DE五K...
for Adult Disease, Nishinomiya. Lung Cancer (Japan) 1994;34:955–1001Show moreShow less Choose an option to locate/access this article: Check if you have access through your login credentials or your institutionCheck access Purchase $35.95 ...